Mild to Moderate Alzheimer's Disease Clinical Trial
Official title:
Efficacy and Safety of Near Infrared Light Therapy for Alzheimer's Disease
To explore the efficacy and safety of near infrared light therapy for Alzheimer's disease. Each subject will be numbered and their medical records will be established. The subjects will be randomly assigned to the treatment group or the control group for 30 minutes/day (5-6 days a week) for 4 months while the treatment group is active settings and the control group is sham settings.Follow-up visits will be conducted at 2 months, 4 months and 2 months after treatment. At each follow-up, scale assessment, blood, MRI, and EEG were observed
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT05189210 -
GV1001 Subcutaneous(SC) for the Treatment of Mild to Moderate Alzheimer's Disease (AD)
|
Phase 2 | |
| Active, not recruiting |
NCT03507790 -
A Study to Evaluate the Safety and Efficacy of CT1812 in Subjects With Mild to Moderate Alzheimer's Disease.
|
Phase 2 | |
| Completed |
NCT02703636 -
NextStep:Study to Evaluate Safety,Efficacy & Tolerability of Rivastigmine Patch in Mild to Moderate Alzheimer's Patients.
|
Phase 4 | |
| Completed |
NCT03867253 -
Testing the Safety and Preliminary Efficacy of the New Drug ORY-2001 in Mild to Moderate Alzheimer's Disease
|
Phase 2 | |
| Completed |
NCT03069014 -
Study of LM11A-31-BHS in Mild-moderate AD Patients
|
Phase 1/Phase 2 | |
| Completed |
NCT01039701 -
4 Week, Safety and Tolerability Study in Patients With Mild to Moderate Alzheimer's Disease
|
Phase 2 | |
| Completed |
NCT03625622 -
Efficacy and Safety of 26-Week Treatment of AR1001 in Patients With Mild to Moderate Alzheimer's Disease
|
Phase 2 |